Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)

被引：7
|
作者：
Leonard, R
Miles, D
Reichardt, P
Twelves, C
机构：
[1] S Wales Canc Inst, Swansea, W Glam, Wales
[2] Guys & St Thomas Hosp, London SE1 9RT, England
[3] HELIOS Klinikum, Dept Hematol Oncol & Tumorimmunol, Berlin, Germany
[4] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England
[5] Bradford Royal Infirm, Bradford BD9 6RJ, W Yorkshire, England
来源：
SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 05期
关键词：
D O I：
10.1053/j.seminoncol.2004.07.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：21 / 28
页数：8
相关论文
共 50 条
  • [31] S-1 versus taxanes for HER2-negative metastatic breast cancer
    Martin, Miguel
    Lopez-Tarruella, Sara
    LANCET ONCOLOGY, 2016, 17 (01): : 11 - 12
  • [32] Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 257 - 257
  • [33] BevacizumabA Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
    Katherine F. Croom
    Sohita Dhillon
    Drugs, 2011, 71 : 2213 - 2229
  • [34] Bevacizumab A Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
    Croom, Katherine F.
    Dhillon, Sohita
    DRUGS, 2011, 71 (16) : 2213 - 2229
  • [35] Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).
    O'Shaughnessy, Joyce
    Young, Robyn R.
    Levin, Maren K.
    Baisch, Jeanine
    Timis, Roxana
    Muniz, Luz Stella
    Turner, Jacob
    Pascual, Virginia
    Palucka, Karolina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
    Nardin, Simone
    Del Mastro, Lucia
    ANNALS OF TRANSLATIONAL MEDICINE, 2023,
  • [37] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [38] Is HER2 expression related to CDKi efficacy in HER2-negative luminal metastatic breast cancer?
    Rodriguez Garces, Maria Yeray
    Fernandez Madrigal, Laura
    Morales Pancorbo, David
    Bayo, Juan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] NCCN Guidelines Updates: Management of Patients With HER2-Negative Breast Cancer
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (5.5): : 561 - 565
  • [40] Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22
12345